The Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne, France, has initiated treatments with a non-invasive brain tumour therapy called the ZAP-X Gyroscopic Radiosurgery platform, manufactured by ZAP Surgical Systems.
This advanced treatment is being offered by CCPSC, which is part of the American Hospital of Paris.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The ZAP-X system is claimed to deliver stereotactic radiosurgery (SRS) with precision, concentrating radiation on the tumour target while minimising damage to healthy brain tissue.
By providing a painless and outpatient treatment option, SRS offers outcomes comparable to or better than traditional surgeries.
Moreover, ZAP-X eliminates the need for shielded radiation treatment rooms and the use of radioactive isotopes, reducing costs.
CCPSC radiation oncologist Dr Bacem Belghith said: “Because of the significant percentage of cancer patients who develop brain metastases, it was imperative we support our radiation oncology program with a dedicated SRS solution such as ZAP-X.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe vault-free design of the ZAP-X platform eliminates the requirement for expensive shielded treatment rooms.
CCPSC radiation oncologist Dr Alain Allaw said: “As ZAP-X is designed specifically for cranial radiosurgery it allows us to treat the most challenging cases with confidence.
“And unlike multi-purpose radiotherapy devices, ZAP-X provides patients with potentially lower healthy brain exposure to radiation, and thus enables greater flexibility for our clinical team to treat recurring brain metastases patients.”
